Article

A Comparison Between Treatment Response of Chronic Myeloid Leukemia Patients Receving Imatinib or Nilotinib

2025-09-01

Abstract excerpt

<h4>Background: </h4> Chronic Myeloid Leukemia (CML) is a myeloproliferative neoplasm driven by the BCR–ABL1 fusion gene. Tyrosine kinase inhibitors (TKIs), such as imatinib and nilotinib, have transformed CML management by significantly improving hematologic and molecular responses. However, real-world data from low- to middle-income countries, including Indonesia, remain limited. Objective This study aimed to ev...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 1317bdf2-5c0f-5ee4-81c0-b46a51ca02ca
DOI: 10.12688/f1000research.168812.1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

A Comparison Between Treatment Response of Chronic Myeloid Leukemia Patients Receving Imatinib or NilotinibDOI 10.12688/f1000research.168812.1Read

A Comparison Between Treatment Response of Chronic Myeloid Leukemia Patients Receving Imatinib or NilotinibSemantic proximity Read

Best First Line Tyrosine Kinase Inhibitor for Chronic Phase Chronic Myeloid Leukemia in Adults: A Network Meta-AnalysisSemantic proximity Read

Optimizing second-line therapy for chronic myeloid leukemia.Semantic proximity Read

Real-Life Data of Patients with Chronic Myeloid Leukemia in AmazonasSemantic proximity Read

Biomarkers for BCR-ABL1 as a Potential Therapeutic Option Among Adult Chronic Myeloid Leukaemia Treated With Tyrosine Kinase Inhibitors at Molecular Response in Multi-racial Malaysia: Hsa-mir-181a-5p for Decrement; hsa-mir-182-5p and hsa-mir-26a-5p for Increment.Semantic proximity Read

Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.Semantic proximity Read

Improved Posttransplant Outcomes in Recent Years for AML Patients with FLT3-ITD and Wild-type NPM1: A Report from the EBMT Acute Leukemia Working Party.Semantic proximity Read

Immune-Related Genes for the Prediction of Response to Imatinib therapy in Chronic Myeloid LeukemiaSemantic proximity Read

Early Dynamics of Chronic Myeloid Leukemia on Nilotinib Predicts Deep Molecular ResponseSemantic proximity Read

Predicting the response of CML patients to tyrosine kinase inhibitor therapy.Semantic proximity Read

Response definitions and European Leukemianet Management recommendations.Semantic proximity Read

Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib.Semantic proximity Read